# Sermorelin Growth Hormone: Aging and the GH/IGF-1 Axis | Sermorelin Research > Sermorelin growth hormone research: GHRH(1-29) reversed age-related declines in 24-hour GH and IGF-1 in healthy older men. What the aging-axis literature on Sermorelin actually shows. The body's growth-hormone output falls with age. GHRH(1-29) was studied as a way to nudge it back up through the pituitary — here is what the older-adult studies measured, and where the data stop. ## The short version As people age, the brain's own growth-hormone signal weakens and the body makes less growth hormone — and less IGF-1, the liver-made growth signal that follows it. The question this page covers is simple: when researchers gave older adults sermorelin growth hormone research doses of GHRH(1-29) (the fragment that prompts the pituitary), did the aging axis move? The clearest study says yes — in healthy older men, two weeks of dosing lifted 24-hour growth hormone and IGF-1 until they looked like a young man's. That is a measured biomarker change in a short study, not a proven anti-aging treatment. The marketing runs ahead of the evidence; this page keeps them apart. ## GH and IGF-1 in Older Men The defining adult finding is precise. In healthy old men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour growth hormone and IGF-1; after the high dose, the GH/IGF-1 parameters no longer differed from those of young men, and fasting glucose was unchanged [5]. In plain terms: a short course pushed an aging hormonal profile back toward a younger one, through the body's own pituitary release rather than injected hormone. That is the result the rest of the adult story leans on, and it is genuinely what the published research establishes for this measure. It is also where the honest framing matters: the study ran 14 days and tracked hormones, not long-term clinical outcomes. The 2025 Nature Reviews Endocrinology synthesis places GHRH(1-29) and its analogues in the wider therapeutic landscape [6], and a 2023 review specifically assessed growth-hormone secretagogues as a way to restore youthful GH-secretion patterns in aging [7]. A 2025 clinical review of growth hormone and aging covers the broader physiology and the intervention evidence [8]. ## Sermorelin Benefits Studied in the GH/IGF-1 Literature The benefits reported for sermorelin are biomarker and growth outcomes, attributed to studies — not lifestyle promises. The pediatric trial measured accelerated growth: first-year height velocity rising from about 4.1 to roughly 7-8 cm/year in growth-hormone-deficient children [2]. The aging study measured the GH/IGF-1 reversal in older men [5]. For the related stabilized analog tesamorelin, a controlled trial reported IGF-1 raised 117% within the physiologic range and percent body fat cut 7.4% over 20 weeks [10]. What is not established is durable adult anti-aging benefit. Rigorous long-term efficacy and safety data for that use are limited, and an Annals of Internal Medicine editorial concluded that using growth-hormone secretagogues to prevent or treat aging is "not yet ready for prime time" [9]. The accurate reading is that the GH/IGF-1 axis moves in these studies; whether moving it produces lasting benefit in healthy aging adults is not answered by this evidence set. ## Where the Marketing Gets Ahead of the Data Two honest caveats frame everything above. First, the approval history is routinely misstated, so state it straight: sermorelin was an FDA-approved drug for growth-hormone deficiency and short stature in children, and it was withdrawn from the US market in 2008 for commercial reasons — not for any safety or efficacy failure. It is not currently a marketed FDA-approved finished drug; it is now prepared by compounding pharmacies and treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A policy (final guidance January 2025). It is also prohibited in sport: growth-hormone secretagogues, including GHRH analogs, sit on the WADA Prohibited List under hormone and metabolic modulators (S2). Second, the adult anti-aging case is where promotion outruns evidence. The biomarker movement in older men is real and short-term [5]; durable clinical anti-aging benefit in healthy adults is not established, and an Annals of Internal Medicine editorial judged secretagogue use for aging "not yet ready for prime time" [9]. This page presents the GH/IGF-1 findings as studied outcomes and marks that gap rather than filling it. ## How Long Does It Take for Sermorelin to Work? Pharmacokinetic studies show growth hormone rises within an hour of a single dose and stays elevated for roughly 3 hours, despite the peptide's short ~10-12 minute plasma half-life [3]. Changes in IGF-1 and body composition in adult research accrued over weeks of repeated dosing [5]. These are study timelines, not a personal one. ## Will Sermorelin Raise IGF-1 Levels? In healthy older men, 14 days of subcutaneous GHRH(1-29) produced dose-related rises in IGF-1, and at the high dose IGF-1 no longer differed from that of young men, with no change in fasting glucose [5]. IGF-1 is made mainly by the liver in response to growth hormone, so the rise follows GH stimulation rather than acting directly. ## How Long Were Sermorelin Studies? Durations vary widely. The adult GH-axis study in older men ran 14 days and still showed reversal of age-related GH/IGF-1 declines [5]; the pediatric efficacy trial measured first-year growth over 12 months [2]. There is no established adult anti-aging duration — long-term adult data remain limited [9]. ## Sermorelin and Fat: What Studies Report The GH/IGF-1 axis has a known role in body composition, and in a controlled cognition trial the stabilized GHRH analog tesamorelin reduced percent body fat by 7.4% over 20 weeks [10]. A review discusses GH/IGF-1-axis modulation among strategies for age-related change [11]. Anti-aging and body-composition marketing outpaces the evidence; these are studied outcomes, not proven benefits. ## Sermorelin, GH/IGF-1 and Muscle A review frames GH/IGF-1-axis modulation, including GHRH secretagogues, among candidate strategies to counteract sarcopenia (age-related muscle loss) in older adults [11]. Sermorelin raises growth hormone and IGF-1, which mediate anabolic signaling, but rigorous adult muscle-outcome data are limited and benefit is not established. Research context only. ## Sermorelin Before and After: Measured Changes in Studies Controlled studies report objective biomarker and growth changes, not anecdotal transformations: dose-related rises in 24-hour GH and IGF-1 in older men, with high-dose values matching young men [5]; first-year height velocity rising from about 4.1 to 7-8 cm/year in growth-hormone-deficient children [2]; and, for the analog tesamorelin, IGF-1 +117% and body fat -7.4% over 20 weeks [10]. --- The sermorelin literature read along one calm horizon — each GH and IGF-1 figure carried back to its study, the formerly-approved-now-compounded history stated straight, and the open water where the adult anti-aging data stop left plainly unfilled; no clinic behind the tide and nothing here dispensed, dosed, or sold.